NSAH?

CAS No. 1099592-35-4

NSAH?( 2-hydroxy-N'-[(E)-(2-hydroxynaphthalen-1-yl)methylidene]benzohydrazide )

Catalog No. M22882 CAS No. 1099592-35-4

NSAH is a nonnucleoside inhibitor of human ribonucleotide reductase (hRR).with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively.A unique nonnucleoside small-molecule hRR inhibitor, naphthyl salicylic acyl hydrazone (NSAH), using virtual screening, binding affinity, inhibition, and cell toxicity assays. NSAH binds to hRRM1 with an apparent dissociation constant of 37 μM, and steady-state kinetics reveal a competitive mode of inhibition.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 58 In Stock
10MG 102 In Stock
25MG 205 In Stock
50MG 335 In Stock
100MG 537 In Stock
500MG 1134 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    NSAH?
  • Note
    Research use only, not for human use.
  • Brief Description
    NSAH is a nonnucleoside inhibitor of human ribonucleotide reductase (hRR).with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively.A unique nonnucleoside small-molecule hRR inhibitor, naphthyl salicylic acyl hydrazone (NSAH), using virtual screening, binding affinity, inhibition, and cell toxicity assays. NSAH binds to hRRM1 with an apparent dissociation constant of 37 μM, and steady-state kinetics reveal a competitive mode of inhibition.
  • Description
    NSAH is a nonnucleoside inhibitor of human ribonucleotide reductase (hRR).with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively.A unique nonnucleoside small-molecule hRR inhibitor, naphthyl salicylic acyl hydrazone (NSAH), using virtual screening, binding affinity, inhibition, and cell toxicity assays. NSAH binds to hRRM1 with an apparent dissociation constant of 37 μM, and steady-state kinetics reveal a competitive mode of inhibition. A 2.66- resolution crystal structure of NSAH in complex with hRRM1 demonstrates that NSAH functions by binding at the catalytic site (C-site) where it makes both common and unique contacts with the enzyme compared with NDP substrates. Importantly, the IC for NSAH is within twofold of gemcitabine for growth inhibition of multiple cancer cell lines, while demonstrating little cytotoxicity against normal mobilized peripheral blood progenitor cells. NSAH depresses dGTP and dATP levels in the dNTP pool causing S-phase arrest, providing evidence for RR inhibition in cells.NSAH (0-10 μM, 2, 6, 24, or 72 h) exhibits potent anti-tumor activity in 3 cancer cell lines.
  • In Vitro
    NSAH depresses dGTP and dATP levels in the dNTP pool causing S-phase arrest, providing evidence for RR inhibition in cells.NSAH (0-10 μM, 2, 6, 24, or 72 h) exhibits potent anti-tumor activity in 3 cancer cell lines.NSAH blocks S-phase progression well to the extent and timing of the decreases in dATP and dGTP. Cell Viability Assay Cell Line:MDA-231, HCT116 and Panc1 cancer cell lines.Concentration:0-10 μM.Incubation Time:2, 6, 24, or 72 h.Result:Resulted in IC50 values ranging from 220 to 500 nM.
  • In Vivo
    ——
  • Synonyms
    2-hydroxy-N'-[(E)-(2-hydroxynaphthalen-1-yl)methylidene]benzohydrazide
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    DNA/RNA Synthesis
  • Recptor
    RR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1099592-35-4
  • Formula Weight
    306.3
  • Molecular Formula
    C18H14N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:62.5 mg/mL (204.03 mM; Need ultrasonic)
  • SMILES
    O=C(C1=CC=CC=C1O)N/N=C/C2=C3C=CC=CC3=CC=C2O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Md Faiz Ahmad, et al. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule. Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8241-8246.
molnova catalog
related products
  • Rifapentine

    Rifapentine is an antibiotic drug used in the treatment of tuberculosis.

  • SR 11302

    SR 11302 is an inhibitor of activator protein-1 (AP-1).

  • Fialuridine

    Fialuridine is a DNA-directed DNA polymerase inhibitor potentially for the treatment of HBV infection with potent activity against hepatitis B virus in vitro and in vivo.